Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HSPC) (HSC (for Hematopoietic stem cell), HSPC (for Hematopoietic progenitor cell))
- Target
- HSC (for Hematopoietic stem cell), HSPC (for Hematopoietic progenitor cell)
- Molecular classification
- Stem cell (HSC), Progenitor cell (HSPC), Other (Cellular therapy target, not a molecular entity)
01
Overview
Hematopoietic reconstitution via hematopoietic stem/progenitor cell engraftment is the process through which transplanted HSCs and HSPCs home to and repopulate stem-cell niches in the recipient's bone marrow, leading to restoration of blood cell production. This process is central to treatments such as bone marrow transplantation and gene therapy approaches for various hematologic diseases. Engraftment success depends on underlying biological and chemical factors in the marrow niche, as well as clinical protocols including conditioning regimens, cell dose, and ex vivo expansion strategies. Monitoring involves cell counts and chimerism, while safety concerns include rejection, infection risk, and immune complications such as GVHD.
- Other names
- hematopoietic reconstitutionstem cell engraftmenthematopoietic stem cell transplantationHSC transplantationbone marrow engraftmentHSPC engraftment
02
Mechanism of action
Immunological reconstitution by donor/recipient engraftment Graft-versus-tumor (e.g., leukemia) effect Correction of genetic defects (gene editing) Competitive repopulation of marrow niches Ex vivo expansion enabling increased engraftment
03
Biological functions
Hematopoiesis (production of blood cells)Immune reconstitutionCell proliferationTissue regenerationEngraftment
04
Disease associations
Cancer (leukemia, lymphoma, myelodysplastic syndromes)Primary immunodeficiencyBone marrow failureSickle cell diseaseOther refractory hematologic disorders
05
Safety considerations
Graft rejectionGraft-versus-host disease (GVHD)Opportunistic infection (due to immune suppression)Delayed engraftment (prolonged cytopenias)Genotoxicity from gene-editingRelapse of underlying diseaseToxicity from preparative regimens (chemotherapy)Insufficient cell dose (especially with cord blood)
06
Interacting drugs
Gene-modifying agents (e.g., CRISPR-Cas9 edited HSPCs for monogenic diseases)
4 more in the full profile.
07
Biomarkers
CD34+ cell count (HSC/HSPC marker, commonly used for selection/monitoring)Chimerism (% donor vs host cells post-transplant)Hematologic indices: ANC (absolute neutrophil count), hemoglobin, plateletsMinimal residual disease (MRD)
Beyond the preview
Go deeper on Hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HSPC) (HSC (for Hematopoietic stem cell), HSPC (for Hematopoietic progenitor cell)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HSPC) (HSC (for Hematopoietic stem cell), HSPC (for Hematopoietic progenitor cell)).